N※N

Vena Vitals Opens New Lab, Boosts Las Vegas Health Tech Scene

  //science-technology.news-articles.net/content/2 .. -new-lab-boosts-las-vegas-health-tech-scene.html
  Published in Science and Technology on Wednesday, March 25th 2026 at 7:01 GMT by FOX5 Las Vegas
      Locale: UNITED STATES

LAS VEGAS, NV - March 25th, 2026 - Vena Vitals, a pioneering health tech startup focused on revolutionizing blood pressure monitoring, officially opened its new research and development laboratory at the Roseman University of Nevada's Summerlin campus today. This expansion marks a significant milestone for the company and further cements Las Vegas's growing reputation as a hub for health technology innovation. The project is predicted to create around 60 high-paying jobs, contributing substantially to the local economy.

For years, accurate and continuous blood pressure monitoring has relied heavily on cumbersome equipment and, in some cases, invasive procedures. Traditional methods often fail to capture the dynamic fluctuations that occur throughout the day, limiting their effectiveness in diagnosing and managing conditions like hypertension. Vena Vitals aims to address these shortcomings with its wearable, non-invasive blood pressure monitoring device. The device utilizes advanced sensor technology and proprietary algorithms to provide real-time, accurate blood pressure readings without the need for cuffs or needles.

CEO Michael Burdette emphasizes the strategic importance of the Roseman University partnership. "Roseman University's commitment to healthcare education and research, combined with its state-of-the-art facilities, provides the ideal environment for us to accelerate our development process and conduct rigorous clinical trials," Burdette stated in a press conference earlier today. "We're not just building a device; we're building a future where proactive health management is accessible to everyone."

Beyond the Device: The Broader Implications for Healthcare

The potential impact of Vena Vitals' technology extends far beyond simply providing more convenient blood pressure readings. Continuous monitoring offers the possibility of early detection of hypertension, even before symptoms manifest. This could be particularly crucial for individuals at high risk, allowing for timely intervention and potentially preventing serious complications like heart disease, stroke, and kidney failure. The data collected by the device can also be seamlessly integrated with telehealth platforms, enabling remote patient monitoring by healthcare professionals. This shift towards remote monitoring could be transformational for managing chronic conditions, particularly in underserved communities with limited access to care.

Industry analysts predict a substantial increase in the adoption of wearable health tech in the coming years, driven by an aging population, a rising prevalence of chronic diseases, and a growing emphasis on preventative healthcare. According to a recent report by Global Health Insights, the wearable blood pressure monitoring market is projected to reach $15 billion by 2030, with a compound annual growth rate of 12%. Vena Vitals is well-positioned to capitalize on this growth, thanks to its innovative technology and strategic partnerships.

Roseman University Benefits from Collaborative Innovation

The partnership between Vena Vitals and Roseman University is a mutually beneficial one. The university gains access to cutting-edge technology and research opportunities for its students and faculty, while Vena Vitals benefits from a skilled workforce and a dedicated research environment. Dr. Jeffrey Clark, Provost of Roseman University, highlighted the synergy between the two organizations. "We are thrilled to welcome Vena Vitals to our Summerlin campus. This collaboration will not only enhance our research capabilities but also provide our students with invaluable hands-on experience in the field of health tech." The university plans to incorporate Vena Vitals' technology into its curriculum, training the next generation of healthcare professionals in the use of advanced monitoring devices.

The City of Las Vegas has also actively courted health tech companies, offering tax incentives and streamlined regulatory processes to attract investment and create jobs. This commitment to fostering innovation is paying off, with Las Vegas rapidly emerging as a prominent center for healthcare technology. The Vena Vitals expansion represents the latest in a series of positive developments, signaling that the city is well on its way to becoming a leading destination for health tech companies.

What's Next for Vena Vitals?

With the new lab fully operational, Vena Vitals is now focused on completing clinical trials and obtaining regulatory approval from the FDA. The company anticipates launching its device to the market in late 2027, initially targeting individuals with hypertension and those at risk of developing the condition. Future plans include expanding the device's capabilities to monitor other vital signs, such as heart rate variability and oxygen saturation, creating a comprehensive, integrated health monitoring platform.